Literature DB >> 12926076

Sensitization of human Ewing's tumor cells to chemotherapy and heat treatment by the bioflavonoid quercetin.

Anette Debes1, Matthias Oerding, Reinhart Willers, Ulrich Göbel, Rüdiger Wessalowski.   

Abstract

BACKGROUND: The bioflavonoid quercetin, a polyphenolic compound widely distributed in the plant kingdom, has been demonstrated to exert cytostatic activity against a variety of tumor cells in vitro and in vivo. It may be useful in cancer therapy as a thermosensitizer by increasing the cell killing effect of hyperthermia and chemotherapy because of its ability to suppress heat-shock protein expression.
MATERIALS AND METHODS: We investigated the effect of quercetin combined with two cytotoxic agents, cDDP (cis-diamminedichloroplatinum II) and VP-16 (etoposide), under various heat-shock conditions in two Ewing's tumor cell lines SK-ES-1 and RD-ES, using XTT-assay and Western blot analysis.
RESULTS: Induction of thermotolerance by a sublethal heat-shock (42 degrees C, 1 hour) led to a transient resistance against subsequent heat treatment alone or combined thermochemotherapy with the crosslinking agent cDDP or the topoisomerase II inhibitor VP-16. Quercetin (> or = 50 microM) applied for 24 hours inhibited cell proliferation, increased the cytotoxic activity of cDDP or VP-16 alone or combined with simultaneous hyperthermia and suppressed the development of thermotolerance. Hyperthermia (43 degrees C, 45 degrees C for 1 hour) induced high expression of the inducible form of HSP70, whereas HSP27, which is constitutively expressed at normothermic conditions, is only slightly induced by 43 degrees C and nearly completely suppressed at 45 degrees C. Induction of thermotolerance is accompanied by an elevated expression of both HSP70 and HSP27. Quercetin (> or = 50 microM), alone as well as in combination with thermochemotherapy, inhibited the expression of both HSP70 and HSP27.
CONCLUSION: These data suggest that the bioflavonoid quercetin potentially may be useful in clinical trials for optimizing the efficacy of hyperthermia in combination with chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12926076

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Pharmacological inhibition of GSK-3β produces late phase of cardioprotection in hyperlipidemic rat: possible involvement of HSP 72.

Authors:  Harlokesh Narayan Yadav; Manjeet Singh; Pyare Lal Sharma
Journal:  Mol Cell Biochem       Date:  2012-07-19       Impact factor: 3.396

2.  Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells.

Authors:  Temesgen Samuel; Khalda Fadlalla; Lachundra Mosley; Venkat Katkoori; Timothy Turner; Upender Manne
Journal:  Anticancer Res       Date:  2012-01       Impact factor: 2.480

3.  PLGA nanoparticles loaded with etoposide and quercetin dihydrate individually: in vitro cell line study to ensure advantage of combination therapy.

Authors:  Smita Pimple; Arehalli S Manjappa; Mukesh Ukawala; R S R Murthy
Journal:  Cancer Nanotechnol       Date:  2012-05-09

4.  Curcumin and Quercetin as Potential Radioprotectors and/or Radiosensitizers for X-ray-based Sterilization of Male Navel Orangeworm Larvae.

Authors:  Pei-Shih Liang; Ronald P Haff; Inna Ovchinnikova; Douglas M Light; Noreen E Mahoney; Jong H Kim
Journal:  Sci Rep       Date:  2019-02-14       Impact factor: 4.379

5.  The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study.

Authors:  A M E Bruynzeel; H W M Niessen; J G F Bronzwaer; J J M van der Hoeven; J Berkhof; A Bast; W J F van der Vijgh; C J van Groeningen
Journal:  Br J Cancer       Date:  2007-10-16       Impact factor: 7.640

6.  Inducible hsp70 in the regulation of cancer cell survival: analysis of chaperone induction, expression and activity.

Authors:  Elisa Zorzi; Paolo Bonvini
Journal:  Cancers (Basel)       Date:  2011-10-21       Impact factor: 6.639

7.  Quercetin sensitizes glioblastoma to t-AUCB by dual inhibition of Hsp27 and COX-2 in vitro and in vivo.

Authors:  Junyang Li; Chao Tang; Liwen Li; Rujun Li; Youwu Fan
Journal:  J Exp Clin Cancer Res       Date:  2016-04-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.